Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Pfizer Inc. PFE on Tuesday reported better-than-expected first-quarter results and reaffirmed its 2026 financial guidance.

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities ...

Investors who seek out dividend stocks pay close attention to a company's dividend yield, and high-yield players -- as long ...